Tysabri and PML: What Washington Patients Should Know About Early Symptoms

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Exposure Analysis

If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) is critical for timely intervention. For decades, medical research has established that PML, a rare brain infection, can emerge during immunosuppressive therapy, and monitoring protocols have evolved to detect it early. This page outlines the key symptoms and follow-up tests recommended for Washington patients on Tysabri.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised individuals and is caused by the JC virus. The clinical presentation of PML can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed by MRI findings and detection of JC virus DNA in cerebrospinal fluid. The prescribing information emphasizes that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and that Tysabri should be withheld immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these monitoring recommendations, PML can still develop, and the outcome is often fatal or leads to severe disability.

Mechanistic Pathway and Warning Adequacy

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance against JC virus, allowing the virus to reactivate and cause PML. The risk is particularly elevated in patients with anti-JCV antibodies, which indicate prior exposure to the virus. From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The boxed warning and the TOUCH Prescribing Program are designed to inform patients and healthcare providers of the risks and to ensure careful monitoring. However, some patients may argue that the warnings were insufficient or that they were not adequately informed about the magnitude of the risk, especially in the context of their individual risk factors. For affected patients in Washington, settlement-related considerations may include whether the manufacturer provided adequate warnings and whether the patient's PML was foreseeable based on known risk factors. The timeline between Tysabri exposure and documented harm is critical for legal claims. PML can develop after varying durations of treatment, with risk increasing after two years of therapy.

Statute of Limitations for Tysabri Claims in Washington

The statute of limitations for product liability claims in Washington is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, the date of diagnosis is often considered the starting point. Patients who developed PML after Tysabri treatment should consult with a legal professional to determine if their claim falls within the applicable time frame. In summary, Tysabri-associated PML is a serious adverse event with well-defined risk factors and a clear mechanistic basis. The FDA-mandated warnings and monitoring programs aim to mitigate this risk, but cases continue to occur. For Washington patients, understanding the medical evidence and the statute of limitations is essential for pursuing any settlement or legal action. The evidence underscores the importance of individualized risk assessment and timely legal consultation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Washington?

In Washington, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, the date of diagnosis is often considered the starting point. It is crucial to consult with a legal professional to determine if your claim falls within the applicable time frame.

What are the risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating or continuing therapy, and the expected benefit must be weighed against the PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.